8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 7, 2019)

Filed January 7, 2019For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced preliminary fourth quarter 2018 financial results, primarily focusing on the commercial performance of its drug ONPATTRO® (patisiran). The company reported unaudited global net product revenues for ONPATTRO in the range of $11 million to $12 million. This pre-announcement provides investors with an early look at the drug's initial sales traction following its launch. In addition to product revenue, Alnylam also updated its year-end cash position guidance. The company now anticipates ending 2018 with approximately $1.1 billion in cash, cash equivalents, marketable securities, and restricted investments (excluding securities). This strong cash balance is a key factor for investors, indicating financial flexibility for ongoing research, development, and commercialization efforts.

Key Highlights

  • 1Preliminary Q4 2018 global net product revenues for ONPATTRO® (patisiran) reported between $11 million and $12 million.
  • 2Updated unaudited cash, cash equivalents, marketable securities, and restricted investments guidance for year-end 2018 to approximately $1.1 billion.
  • 3The announcement focuses on early commercial launch updates for ONPATTRO.
  • 4Information provided is a pre-announcement and not deemed "filed" under Section 18 of the Exchange Act.
  • 5The filing includes a press release dated January 7, 2019, as Exhibit 99.1.

Frequently Asked Questions

The key financial takeaways are the preliminary unaudited Q4 2018 net product revenues for ONPATTRO, which are estimated to be between $11 million and $12 million, and the updated year-end 2018 cash position guidance, expected to be around $1.1 billion.

The pre-announcement indicates that ONPATTRO generated $11-12 million in global net product revenues in its first full or partial quarter of launch, suggesting some initial market uptake.

The projected cash balance of $1.1 billion at year-end 2018 provides Alnylam with significant financial resources. This suggests a strong ability to fund ongoing operations, research and development programs, and future commercial expansion without immediate financing concerns.

No, the information in Item 2.02 and Exhibit 99.1 is explicitly stated as being furnished, not filed. Therefore, it is not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated into other filings.